Pediatric MS, MOGAD and NMOSD : Similarities and Differences

Dr Silvia Tenembaum is a pediatric neurologist who received her MD with honours, from the School of Medicine, University of Buenos Aires, and acquired further specialization in pediatric neurology in Argentina. She is currently Chief of Clinics and Chair of the Pediatric Neuroimmunology Program at the Department of Neurology, National Pediatric Hospital Dr Juan P. Garrahan in Buenos Aires. She has had a longstanding interest in acquired inflammatory demyelinating disorders with pediatric onset and has established a Comprehensive Care Clinic for children with multiple sclerosis, neuromyelitis optica and related disorders.

She is founding member of the International Paediatric MS Study Group (IPMSSG), past-Chair of its Steering and Nominating Committees. She is currently an executive board member of the International Child Neurology Association (ICNA), and member of several leading neurology societies, including the Latin-American Committee for Treatment and Research in Multiple Sclerosis (LACTRIMS), the NMO Roundtable Study Group, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the Argentinian Society of Child Neurology (SANI), and the Argentinian Society of Neurology (SAN). She has been an active member of the International Panel for Neuromyelitis Optica Diagnosis (IPND), and currently member of the GJCF International Clinical Consortium (ICC).

Dr. Tenembaum is an Editorial Board member of the following journals: Neurology: Neuroimmunology & Neuroinflammation, Frontiers in Neurology, and Neurology and Therapy. She also serves as an expert reviewer for many journals. She has authored numerous papers, as well as chapters in national and international books. She has also been invited to chair or lecture multiple expert meetings, both nationally and internationally.

Her current research focuses on the identification of novel biomarkers of autoimmune neurological disorders in children, the identification of clinical and neuroimaging characteristics of autoimmune CNS disorders targeting aquaporin-4 and myelin oligodendrocyte glycoprotein (MOG) antibodies and optimizing the clinical management and treatment outcome of pediatric MS and NMOSD.